Back to News
Market Impact: 0.25
J&J's Tremfya Shows Sustained Remission In Crohn's Disease Through 3 Years
Source: Nasdaq
Healthcare & BiotechCompany Fundamentals
Johnson & Johnson reported three-year data showing sustained clinical and endoscopic remission with Tremfya (guselkumab) in adults with moderately to severely active Crohn's disease. The report did not provide remission rates or other numerical results.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.35
Ticker Sentiment
JNJ0.65
More News
- J&J's 6% slide on an imperfect quarter is a gift to prospective buyers
- J&J beats earnings estimates; Middle East conflict weighs on medical-device sales
- Johnson & Johnson shares SLIDE nearly 6% despite stronger full-year forecast
- Johnson & Johnson raises 2026 guidance as quarterly sales climb
- Jim Cramer bucks all the stock market negativity with 3 buy recommendations
- Stocks making the biggest moves premarket: JPMorgan Chase, Micron, UnitedHealth & more